NCT02081118View on ClinicalTrials.gov

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

HM11260C

HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

DRUG

Placebo

Placebo for HM11260C

Trial Locations (1)

Unknown

Hanmi pharmaceutical, Miami

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02081118 - Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Biotech Hunter | Biotech Hunter